To develop SARS-CoV-2 replicons that can be used for high throughput screens at BSL2 containment, and to use genetic knockdown and knockout technology to identify host factors required by SARS-CoV-2 that can be targeted to treat COVID-19.
- Funded by Emergent Ventures Fast Grants
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Emergent Ventures Fast GrantsPrincipal Investigator
Dr. Charles RiceResearch Location
United States of AmericaLead Research Institution
The Rockefeller UniversityResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnosticsResearch Subcategory
Pathogen morphology, shedding & natural historySpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable